Search results for "Acetyl-L-carnitine"

showing 3 items of 3 documents

Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy : A systematic review and meta-analysis

2017

Background/aim: Deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a role in peripheral diabetic neuropathy, although the evidence in humans is still limited. We conducted a systematic review and meta-analysis investigating the effect of ALC on pain and electromyographic parameters in people with diabetic neuropathy. Methods: A literature search in major databases, without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) or pre-and post-test studies. The effect of ALC supplementation on pain perception and electromyographic parameters in patients with diabetic neuropathy was compared vs. a control group (RCTs). The effe…

medicine.medical_specialtyDiabetic neuropathyDiabetePlaceboNerve conduction velocitylaw.inventionRATS03 medical and health sciencesGLUTAMATE0302 clinical medicineRandomized controlled triallawDiabetes mellitusMedicineQUALITYMeta-analysi030212 general & internal medicineUlnar nerveAdverse effectbusiness.industryDiabetesNERVE GROWTH-FACTORPAINmedicine.diseaseAcetyl-L-carnitine3. Good healthSurgeryNeuropathyAcetyl-L-carnitine; Diabetes; Meta-analysis; Neuropathy; Gerontology; Geriatrics and GerontologyMeta-analysisPeripheral neuropathyAnesthesia3121 General medicine internal medicine and other clinical medicineGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgeryCLINICAL-TRIALS
researchProduct

Effects of acetyl-l-carnitine in diabetic neuropathy and other geriatric disorders

2018

A long history of diabetes mellitus and increasing age are associated with the onset of diabetic neuropathy, a painful and highly disabling complication with a prevalence peaking at 50% among elderly diabetic patients. Acetyl-l-carnitine (ALC) is a molecule derived from the acetylation of carnitine in the mitochondria that has an essential role in energy production. It has recently been proposed as a therapy to improve the symptoms of diabetic neuropathy. ALC is widely distributed in mammalian tissues, including the brain, blood–brain barrier, brain neurons, and astrocytes. Aside from its metabolic activity, ALC has demonstrated cytoprotective, antioxidant, and antiapoptotic effects in the …

0301 basic medicineNervous systemAgingmedicine.medical_specialtyDiabetic neuropathyDiabetic neuropathyPainNeurotrophic effectAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effect; Aging; Geriatrics and GerontologyNO03 medical and health sciences0302 clinical medicineDiabetic NeuropathiesAlzheimer DiseaseInternal medicineDiabetes mellitusmedicineHumansCarnitineAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effectAcetylcarnitineAcetyl-l-carnitine Diabetic neuropathy Analgesia Neurotrophic effectAgedAnalgesicsbusiness.industryGlutamate receptormedicine.diseaseMitochondriaAcetyl-l-carnitine030104 developmental biologyNerve growth factorEndocrinologymedicine.anatomical_structureAnalgesiaGeriatrics and GerontologyAlzheimer's diseaseAcetylcarnitinebusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct